MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Diabetes (Glucometers, Glucose Monitoring, Continuous Glucose Monitoring [CGM] Companies)
Senseonics Holdings Inc. (NASDAQ: SENS), formerly Sensors for Medicine and Science (SMSI)*
Organization & Developments: Senseonics
Parents
Senseonics Holdings Inc. (NASDAQ: SENS), formerly Sensors for Medicine and Science (SMSI)*
Children
*According to the International Diabetes Foundation, the number of diabetics worldwide is expected to grow from 387 million people in 2014 to 592 million by 2035.
*Eversense is an implantable, long-term CGM system that is intended to accurately measure blood glucose levels on a continuous basis for up to 90 days, which is much longer than current CGM systems that can measure glucose levels for five to seven days.
*Fluorescence molecular sensing technologies.
*Glucose monitor is implanted under the skin of the forearm & connects to watch like monitor
*Its first generation continuous glucose monitoring system (CGM), Eversense, measures glucose levels in people with diabetes.
*SMSI’s continuous glucose monitoring system includes a small sensor, which is implanted under the skin, and an external watch-like display for viewing readings.
*The company is commercializing two product suites: a minimally invasive glucose monitor for diabetics and an oxygen sensor to me
*The U.S. Food and Drug Administration gave the company an investigational device exemption to begin clinical trials in the United States, which Senseonics initiated in the first quarter of 2016.
2017: Senseonics keeps busy with Europe launch, Roche partnerships while FDA wait continues
2018: Is Eversense the Latest Game Changer in the Diabetes Market?
2018: Senseonics reports increase in revenue, looks towards US expansion
2019: Roche, Senseonics extend diabetes monitor distribution deal to BRIC countries
2020: Senseonics Holdings Is A Winner With The Ascensia Deal In Glucose Monitoring
2021: It has 519 issued patents and pending patent applications related to their CGM system and has burned through $648 MM since its inception just to get to where we are now.
2021: Senseonics: A Potential Multi-Bagger From Here
2024: Senseonics receives FDA clearance for one-year CGM
2025: Revisiting Senseonics After 4 Years: Still A Big Investment Opportunity
2025: Senseonics Holdings' Metrics Potentially Highlight Launch-Driven Growth, Not Sustainability
Jumps
*Key People: Senseonics
Finance & Acquisitions: Senseoincs